pharma news today obesity drugs glp-1 september 2025 medications like Ozempic, Wegovy and Mounjaro are changing diabetes and weight management, but they aren't recommended during pregnancy or while nursing. The current recommendation is to stop before conception and discuss FDA takes aim at telehealth

The incidence of diabetes is on the rise with 11.3 percent of the US population (37.3 million or roughly one in ten Americans) currently having the condition

Protein & Macronutrient Blends Dominate Product Preference The protein & macronutrient blends segment held a 39.4% share in 2024 and is projected to reach 43% in 2025

These medications affect weight loss through multiple mechanisms: Appetite Regulation: GLP-1 medications interact with brain receptors that control hunger signals, helping reduce food cravings and overall calorie intake Blood Sugar Management: These medications improve blood sugar levels by enhancing insulin secretion when blood glucose is elevated Gastric Emptying: GLP-1 medications slow the movement of food from the stomach to the small intestine, promoting feelings of fullness Metabolic Effects: These drugs can influence metabolic rate and fat storage patterns in ways that support sustainable weight loss These combined effects can lead to significant weight reduction when used as part of a comprehensive treatment plan that includes lifestyle modifications

Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease

Key Features : Telehealth consultations : Convenient online doctor visits from the comfort of your home